Market Cap | 37.53K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -28.14M | Forward P/E | 0.00 | EPS next Y | - | 50D Avg Chg | -74.00% |
Sales | 6.83M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -98.00% |
Dividend | N/A | Price/Book | 0.03 | EPS next 5Y | 20.00% | 52W High Chg | -100.00% |
Recommedations | 2.00 | Quick Ratio | 0.62 | Shares Outstanding | 10.72M | 52W Low Chg | 250.00% |
Insider Own | - | ROA | -62.13% | Shares Float | 10.72M | Beta | 0.14 |
Inst Own | - | ROE | -210.99% | Shares Shorted/Prior | 374.24K/178.08K | Price | 0.00350 |
Gross Margin | 16.39% | Profit Margin | - | Avg. Volume | 10,104 | Target Price | - |
Oper. Margin | -276.84% | Earnings Date | May 8 | Volume | 306 | Change | 0.00% |
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.